[HTML][HTML] The clinical progress of mRNA vaccines and immunotherapies
The emergency use authorizations (EUAs) of two mRNA-based severe acute respiratory
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
syndrome coronavirus (SARS-CoV)-2 vaccines approximately 11 months after publication of …
[HTML][HTML] Nanomaterial delivery systems for mRNA vaccines
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …
development of lipid nanoparticle delivery systems that not only efficiently express the …
[HTML][HTML] Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination
A Watad, G De Marco, H Mahajna, A Druyan, M Eltity… - Vaccines, 2021 - mdpi.com
Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …
immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines …
[HTML][HTML] mRNA vaccines for COVID-19: what, why and how
JW Park, PNP Lagniton, Y Liu… - International journal of …, 2021 - ncbi.nlm.nih.gov
Abstract The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), has impacted human lives in the most …
respiratory syndrome coronavirus-2 (SARS-CoV-2), has impacted human lives in the most …
[HTML][HTML] COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
Principles for designing an optimal mRNA lipid nanoparticle vaccine
mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of
therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA …
therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA …
[HTML][HTML] The promise of mRNA vaccines: a biotech and industrial perspective
NAC Jackson, KE Kester, D Casimiro, S Gurunathan… - npj Vaccines, 2020 - nature.com
Abstract mRNA technologies have the potential to transform areas of medicine, including the
prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration …
prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration …
[HTML][HTML] Advances in mRNA vaccines for infectious diseases
C Zhang, G Maruggi, H Shan, J Li - Frontiers in immunology, 2019 - frontiersin.org
During the last two decades, there has been broad interest in RNA-based technologies for
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …
the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have …
Challenges in developing personalized neoantigen cancer vaccines
PD Katsikis, KJ Ishii, C Schliehe - Nature Reviews Immunology, 2024 - nature.com
The recent success of cancer immunotherapies has highlighted the benefit of harnessing the
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …
immune system for cancer treatment. Vaccines have a long history of promoting immunity to …
Advances in gene-based vaccine platforms to address the COVID-19 pandemic
D Pushparajah, S Jimenez, S Wong, H Alattas… - Advanced drug delivery …, 2021 - Elsevier
The novel betacoronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus
2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan …
2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan …